Radioactive antibody takes aim at Hard-to-Treat cancers
NCT ID NCT05204147
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 37 times
Summary
This early-stage study tests a new treatment for people with advanced colorectal or other cancers that make a protein called CEA. The treatment, Ac225-DOTA-M5A, is an antibody that seeks out CEA on cancer cells and delivers a radioactive payload to kill them. The main goals are to find the safest dose and understand side effects. About 20 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.